{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:39:53Z","timestamp":1791430793718,"version":"4.3.3"},"reference-count":39,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.urolonc.2024.04.006","type":"journal-article","created":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T09:56:31Z","timestamp":1716112591000},"page":"291.e13-291.e25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience"],"prefix":"10.1016","volume":"42","author":[{"given":"Sanjana","family":"Ranganathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Riveros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqiong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2345-6301","authenticated-orcid":false,"given":"Zachary","family":"Melchiode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Efstathiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith Syson","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.D.","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru","family":"Sonpavde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Satkunasivam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2024.04.006_bib0001","unstructured":"Cancer Facts & Figures 2022. American Cancer Society; 2022."},{"key":"10.1016\/j.urolonc.2024.04.006_bib0002","series-title":"StatPearls","article-title":"Bladder Cancer","author":"Kaseb","year":"2022"},{"issue":"1","key":"10.1016\/j.urolonc.2024.04.006_bib0003","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1097\/j.pbj.0000000000000127","article-title":"Long lasting complete response with immunotherapy in a metastatic bladder carcinoma: a case report","volume":"6","author":"Magalh\u00e3es","year":"2021","journal-title":"Porto Biomed J"},{"issue":"2","key":"10.1016\/j.urolonc.2024.04.006_bib0004","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.urolonc.2024.04.006_bib0005","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.urolonc.2016.10.017","article-title":"Emerging role of immunotherapy in urothelial carcinoma-Advanced disease","volume":"34","author":"Zibelman","year":"2016","journal-title":"Urol Oncol"},{"issue":"17","key":"10.1016\/j.urolonc.2024.04.006_bib0006","doi-asserted-by":"crossref","first-page":"4411","DOI":"10.3390\/cancers13174411","article-title":"Immune checkpoint inhibitors in urothelial bladder cancer: state of the art and future perspectives","volume":"13","author":"Roviello","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.urolonc.2024.04.006_bib0007","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.3390\/cancers14102545","article-title":"Immune checkpoint inhibitors as a neoadjuvant\/adjuvant treatment of muscle-invasive bladder cancer: a systematic review","volume":"14","author":"Barone","year":"2022","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.urolonc.2024.04.006_bib0008","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1007\/s12094-020-02316-8","article-title":"The efficacy and safety of immunotherapy targeting the PD-1 pathway for advanced urothelial carcinoma: a meta-analysis of published clinical trials","volume":"22","author":"Zhang","year":"2020","journal-title":"Clin Transl Oncol"},{"issue":"11","key":"10.1016\/j.urolonc.2024.04.006_bib0009","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.04.006_bib0010","article-title":"Advances and controversies with checkpoint inhibitors in bladder cancer","volume":"15","author":"Rhea","year":"2021","journal-title":"Clin Med Insights: Oncol"},{"issue":"11","key":"10.1016\/j.urolonc.2024.04.006_bib0011","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.urolonc.2024.04.006_bib0012","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1200\/JCO.19.01213","article-title":"Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer","volume":"38","author":"Vuky","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10236","key":"10.1016\/j.urolonc.2024.04.006_bib0013","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2024.04.006_bib0014","doi-asserted-by":"crossref","first-page":"LBA441","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA441","article-title":"Final overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy (chemo) in untreated locally advanced or metastatic urothelial carcinoma (mUC) from the Phase 3 IMvigor130 study","volume":"41","author":"Bamias","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2024.04.006_bib0015","doi-asserted-by":"crossref","first-page":"LBA440","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA440","article-title":"Atezolizumab (atezo)\u202f+\u202fplatinum\/gemcitabine (plt\/gem) vs placebo\u202f+\u202fplt\/gem for first-line (1L) treatment (tx) of locally advanced or metastatic urothelial carcinoma (mUC): Final OS from the randomized Phase 3 IMvigor130 study","volume":"41","author":"Galsky","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.urolonc.2024.04.006_bib0016","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.04.006_bib0017","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/cam4.4917","article-title":"Racial inequity and other social disparities in the diagnosis and management of bladder cancer","volume":"12","author":"Hasan","year":"2023","journal-title":"Cancer Med"},{"issue":"9","key":"10.1016\/j.urolonc.2024.04.006_bib0018","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.15656","article-title":"Association of sociodemographic factors with immunotherapy receipt for metastatic melanoma in the US","volume":"3","author":"Moyers","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.urolonc.2024.04.006_bib0019","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.19535","article-title":"Association between food and drug administration approval and disparities in immunotherapy use among patients with cancer in the US","volume":"5","author":"Ermer","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.urolonc.2024.04.006_bib0020","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1001\/jamaoncol.2016.6905","article-title":"Using the National Cancer Database for outcomes research: a review","volume":"3","author":"Boffa","year":"2017","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.04.006_bib0021","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/imm.12459","article-title":"New clinical advances in immunotherapy for the treatment of solid tumours","volume":"145","author":"Zavala","year":"2015","journal-title":"Immunology"},{"issue":"8","key":"10.1016\/j.urolonc.2024.04.006_bib0022","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1177\/0962280218781171","article-title":"Propensity score weighting analysis and treatment effect discovery","volume":"28","author":"Mao","year":"2019","journal-title":"Stat Methods Med Res"},{"issue":"3","key":"10.1016\/j.urolonc.2024.04.006_bib0023","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/EDE.0000000000000627","article-title":"Matching weights to simultaneously compare three treatment groups: comparison to three-way matching","volume":"28","author":"Yoshida","year":"2017","journal-title":"Epidemiology"},{"issue":"6973","key":"10.1016\/j.urolonc.2024.04.006_bib0024","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/bmj.310.6973.170","article-title":"Multiple significance tests: the Bonferroni method","volume":"310","author":"Bland","year":"1995","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.urolonc.2024.04.006_bib0025","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.04.006_bib0026","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s40425-019-0782-y","article-title":"Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma","volume":"7","author":"Krimphove","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.urolonc.2024.04.006_bib0027","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1002\/cncr.32817","article-title":"Use of immunotherapy and surgery for stage IV melanoma","volume":"126","author":"Molina","year":"2020","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2024.04.006_bib0028","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/CJI.0000000000000253","article-title":"Racial and insurance-related disparities in delivery of immunotherapy-type compounds in the United States","volume":"42","author":"Verma","year":"2019","journal-title":"J Immunother"},{"issue":"1","key":"10.1016\/j.urolonc.2024.04.006_bib0029","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.clgc.2020.07.006","article-title":"Cost-effectiveness of pembrolizumab versus carboplatin-based chemotherapy as first-line treatment of PD-L1-positive locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-based therapy in the United States","volume":"19","author":"Hale","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2024.04.006_bib0030","article-title":"Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: a cost-effectiveness analysis","volume":"13","author":"Liu","year":"2022","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.urolonc.2024.04.006_bib0031","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1007\/s12325-021-01785-9","article-title":"Cost-effectiveness of atezolizumab plus chemotherapy as first-line therapy for metastatic urothelial cancer","volume":"38","author":"Qin","year":"2021","journal-title":"Adv Ther"},{"issue":"19","key":"10.1016\/j.urolonc.2024.04.006_bib0032","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.04.006_bib0033","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejca.2021.03.049","article-title":"First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: a systematic review and meta-analysis","volume":"151","author":"Mori","year":"2021","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2024.04.006_bib0034","doi-asserted-by":"crossref","first-page":"107.e11","DOI":"10.1016\/j.urolonc.2021.07.030","article-title":"Comparative effectiveness analysis of first-line immunotherapy versus chemotherapy in metastatic urothelial carcinoma of the bladder","volume":"40","author":"Chakiryan","year":"2022","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.04.006_bib0035","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.eururo.2019.07.032","article-title":"Effectiveness of first-line immune checkpoint blockade versus carboplatin-based chemotherapy for metastatic urothelial cancer","volume":"76","author":"Feld","year":"2019","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.04.006_bib0036","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/bjc.2013.725","article-title":"Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence","volume":"110","author":"Booth","year":"2014","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.urolonc.2024.04.006_bib0037","doi-asserted-by":"crossref","first-page":"199.e15","DOI":"10.1016\/j.urolonc.2022.03.013","article-title":"An evaluation of trends in the representation of patients by age, sex, and diverse race\/ethnic groups in bladder and kidney cancer clinical trials","volume":"40","author":"Javier-DesLoges","year":"2022","journal-title":"Urol Oncol"},{"issue":"10","key":"10.1016\/j.urolonc.2024.04.006_bib0038","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.12869","article-title":"Feasibility of using real-world data to replicate clinical trial evidence","volume":"2","author":"Bartlett","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1016\/j.urolonc.2024.04.006_bib0039","doi-asserted-by":"crossref","first-page":"410","DOI":"10.46883\/ONC.2021.3507.0410","article-title":"Combination therapy with immune checkpoint inhibitors in urothelial carcinoma: current data and future outlook","volume":"35","author":"Feng","year":"2021","journal-title":"Oncology (Williston Park)"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924004289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924004289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T02:13:25Z","timestamp":1718849605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924004289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1078143924004289"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.04.006","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}